{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T06:24:13Z","timestamp":1698042253380},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1986,9,1]],"date-time":"1986-09-01T00:00:00Z","timestamp":525916800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1986,9]]},"DOI":"10.1007\/bf00253060","type":"journal-article","created":{"date-parts":[[2004,10,3]],"date-time":"2004-10-03T17:37:35Z","timestamp":1096825055000},"page":"33-38","source":"Crossref","is-referenced-by-count":10,"title":["Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion"],"prefix":"10.1007","volume":"18","author":[{"given":"N. Simon","family":"Tchekmedyian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merrill J.","family":"Egorin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian E.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard S.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Poplin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Aisner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF00254539","volume":"7","author":"J Aisner","year":"1982","unstructured":"Aisner J, Van Echo D, Whitacre M, Wiernik P (1982) A phase I trial of continuous infusion VP16-213 (etoposide). Cancer Chemother Pharmacol 7: 157","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR2","first-page":"226","volume":"33","author":"CM Begley Jr","year":"1973","unstructured":"Begley CM Jr, Bostick FW, DeVita VT Jr (1973) Clinical pharmacology of cyclophosphamide. Cancer Res 33: 226","journal-title":"Cancer Res"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00000421-198306000-00018","volume":"6","author":"AJ Bedikian","year":"1983","unstructured":"Bedikian AJ, Bodey GP (1983) Phase I study of cyclophosphamide (NSC 28271) by 72-hour continuous intravenous infusion. Am J Clin Oncol 6: 365","journal-title":"Am J Clin Oncol"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"945","DOI":"10.7326\/0003-4819-90-6-945","volume":"90","author":"JM Bennet","year":"1979","unstructured":"Bennet JM, Reich SD (1979) Bleomycin. Ann Intern Med 90: 945","journal-title":"Ann Intern Med"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0305-7372(80)80006-5","volume":"7","author":"GP Bodey","year":"1980","unstructured":"Bodey GP, Yap HY, Yap BS, Valdivieso M (1980) Continuous infusion vindesine in solid tumors. Cancer Treat Rev 7 (Suppl): 39","journal-title":"Cancer Treat Rev"},{"key":"CR6","first-page":"233","volume":"37","author":"WR Bruce","year":"1966","unstructured":"Bruce WR, Meeker BE, Valeriote FA (1966) Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 37: 233","journal-title":"J Natl Cancer Inst"},{"key":"CR7","first-page":"1441","volume":"61","author":"PA Cassileth","year":"1977","unstructured":"Cassileth PA, Katz ME (1977) Chemotherapy for adult acute non-lymphocytic leukemia with daunorubicin and cytosine arabinoside. Cancer Treat Rep 61: 1441","journal-title":"Cancer Treat Rep"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1476-5381.1971.tb07199.x","volume":"43","author":"JL Cohen","year":"1971","unstructured":"Cohen JL, Lao JY, Jusko WJ (1971) Pharmacokinetics of cyclophosphamide in man. Br J Pharmacol 43: 677","journal-title":"Br J Pharmacol"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0014-2964(79)90198-1","volume":"19","author":"M D'Incalci","year":"1979","unstructured":"D'Incalci M, Bolis G, Facchinetti T, Mangioni C, Morascol L, Morazzoni P, Salmona M (1979) Decreased half-life of cyclophosphamide in patients under continual treatment. Eur J Cancer 19: 7","journal-title":"Eur J Cancer"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1021\/ac60175a029","volume":"33","author":"OM Friedman","year":"1961","unstructured":"Friedman OM, Boger E (1961) Colorimetric estimation of nitrogen mustards in aqueous media. Anal Chem 33: 906","journal-title":"Anal Chem"},{"key":"CR11","first-page":"117","volume":"6","author":"JZ Fuks","year":"1981","unstructured":"Fuks JZ, Egorin MJ, Aisner J, Ostrow SS, Klein ME, Bachur NR, Colvin M, Wiernik PH (1981) Cyclophosphamide of dimethylsulfoxide in the treatment of squamous carcinoma of the lung. Cancer Chemother Pharmacol 6: 117","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2165\/00003088-197904050-00004","volume":"4","author":"LB Grochow","year":"1979","unstructured":"Grochow LB, Colvin OM (1979) Clinical pharmacokinetics of i.v. cyclophosphamide. Clin Pharmacokinet 4: 380","journal-title":"Clin Pharmacokinet"},{"key":"CR13","first-page":"408","volume":"38","author":"I Jardine","year":"1978","unstructured":"Jardine I, Fenselau C, ppler M, Kan MN, Brundrett RB, Colvin M (1978) Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy. Cancer Res 38: 408","journal-title":"Cancer Res"},{"key":"CR14","first-page":"229","volume":"1","author":"FD Juma","year":"1978","unstructured":"Juma FD, Rogers KJ, Trounce JR, Brodbook JD (1978) Pharmacokinetics of intravenous cyclophosphamide in man estimated by gas-liquid chromatography. Cancer Chemother Pharmacol 1: 229","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2125.1979.tb01004.x","volume":"8","author":"FD Juma","year":"1979","unstructured":"Juma FD, Rogers JH, Trounce JR (1979) Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br J Clin Pharmacol 8: 209","journal-title":"Br J Clin Pharmacol"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/1097-0142(19840915)54:1+<1193::AID-CNCR2820541317>3.0.CO;2-Z","volume":"54","author":"HO Klein","year":"1984","unstructured":"Klein HO, wickramanayake PD, Christian E, Coerper C (1984) Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta 27557). Cancer 54: 1193","journal-title":"Cancer"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0010-468X(79)90075-8","volume":"10","author":"GD Knott","year":"1979","unstructured":"Knott GD, (1979) MLAB, A mathematical model tool. Comput Prog Biomed 10: 271","journal-title":"Comput Prog Biomed"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood.V67.1.182.182","volume":"67","author":"EJ Lee","year":"1986","unstructured":"Lee EJ, Van Echo DA, Egorin MJ, Nayar MSB, Shulman P, Schiffer CA (1986) Diaziquone given as a continuous infusion is an active agent for relapsed adult acute nonlymphocytic leukemia. Blood 67: 182","journal-title":"Blood"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-96-2-133","volume":"96","author":"SS Legha","year":"1982","unstructured":"Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich EJ (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96: 133","journal-title":"Ann Intern Med"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1600-0773.1974.tb00729.x","volume":"35","author":"HT Mouridsen","year":"1974","unstructured":"Mouridsen HT, Faber O, Skovsted L (1974) The biotransformation of cyclophosphamide in man: Analysis of the variation in normal subjects. Acta Pharmacol Toxicol (Copenh) 35: 98","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"CR21","first-page":"213","volume":"65","author":"A Salidoro","year":"1981","unstructured":"Salidoro A, Otero J, Vallejos C, Casanova L, Salas F, Pasco T, Quinoz L, Orlandini O, Marcial J (1981) Intermittent continuous i.v. infusion of high-dose cyclophosphamide for remission induction in acuty lymphocytic leukemia. Cancer Treat Rep 65: 213","journal-title":"Cancer Treat Rep"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/1097-0142(197507)36:1<123::AID-CNCR2820360108>3.0.CO;2-C","volume":"36","author":"P Seifert","year":"1975","unstructured":"Seifert P, Baker L, Reed M, Vaitkevicius VK (1975) Comparison of continuously infused 5-fluorouracil with bolus injection in the treatment of patients with colorectal adenocarcinoma. Cancer 36: 123","journal-title":"Cancer"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0305-7372(83)80023-1","volume":"10","author":"R Stuart-Harris","year":"1983","unstructured":"Stuart-Harris R, Harper PG, Kaye SB, Wiltshaw E (1983) High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma. Cancer Treat Rev 10: 163","journal-title":"Cancer Treat Rev"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00253060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00253060\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00253060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T07:47:57Z","timestamp":1585900077000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00253060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1986,9]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1986,9]]}},"alternative-id":["BF00253060"],"URL":"https:\/\/doi.org\/10.1007\/bf00253060","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1986,9]]}}}